序号股票简称PE(TTM)PE(静)市净率总市值(元)5中国石化15.3013.760.836923.10亿行业平均 12.8311.541.201833.77亿行业中值30.4834.631.6561.75亿1中国海油9.188.971.5812372.05亿2中国石油 9.499.551.0015721.50亿3广汇能源12.2311.771.26348.36亿4*ST新潮13.4413.301.18270.66亿6洲际油气 23.0820.511.1599.99亿7泰山石油24.6933.253.0233.03亿8东华能源36.2636.001.44159.82亿9康普顿 45.3655.432.5830.29亿10广聚能源61.4966.332.2864.31亿11和顺石油87.5997.681.7328.59亿12岳阳兴长 107.3593.762.7259.19亿 来源：金融界 8月5日，中国石化今日收盘5.71元，上涨1.06%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到15.30倍，总市值6923.10亿元。 中国石油化工股份有限公司的主营业务为石油及天然气和化工业务。石油及 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of ShenKai Co., which closed at 9.98 yuan with a 3.10% increase, resulting in a rolling PE ratio of 67.08 times and a total market value of 3.632 billion yuan [1][2] - ShenKai Co. operates in the specialized equipment industry, which has an average PE ratio of 72.72 times and a median of 57.38 times, placing ShenKai at the 176th position in the industry ranking [1][2] - As of April 30, 2025, the number of shareholders in ShenKai Co. is 60,721, a decrease of 13,650 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - The main business of ShenKai Co. includes research, development, manufacturing, and sales of equipment in the oil exploration, drilling, and refining sectors, with key products such as oil drilling equipment, logging equipment, and oil analysis instruments [1] - In the latest quarterly report for Q1 2025, ShenKai Co. reported an operating revenue of 202 million yuan, a year-on-year increase of 41.78%, and a net profit of 18.46 million yuan, reflecting a significant year-on-year growth of 434.81%, with a gross profit margin of 33.79% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive diagnostic and therapeutic instruments [1][2] - As of August 4, Anjiasi's stock closed at 81.33 yuan, reflecting a 2.13% increase, with a rolling price-to-earnings (PE) ratio of 22.19 times and a total market capitalization of 6.586 billion yuan [1] - The average PE ratio for the medical device industry is 54.32 times, with a median of 38.11 times, positioning Anjiasi at the 48th rank within the industry [1][2] Group 2 - As of July 31, 2025, Anjiasi has 5,365 shareholders, an increase of 202 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company specializes in the research, production, and sales of endoscopic minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - In the latest quarterly report for Q1 2025, Anjiasi reported a revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.248 million yuan, reflecting a year-on-year growth of 6.57%, with a gross profit margin of 70.68% [1]

Core Insights - Zhendermedical's stock closed at 22.42 yuan, up 1.04%, with a rolling PE ratio of 16.46, marking a new low in 145 days, and a total market capitalization of 5.974 billion yuan [1] - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Zhendermedical at 36th position in the industry ranking [1] - As of the first quarter of 2025, three institutions held shares in Zhendermedical, with a total of 1.4513 million shares valued at 0.031 billion yuan [1] Company Overview - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including recognition as a provincial key enterprise research institute and a national high-tech enterprise [1] Financial Performance - In the first quarter of 2025, Zhendermedical reported revenue of 0.992 billion yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, reflecting a year-on-year decrease of 30.19%, with a sales gross margin of 34.28% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Lepu Medical, indicating a significant decline in revenue and profit compared to the previous year [1][2] - As of August 4, Lepu Medical's stock closed at 16.15 yuan, with a 3.00% increase, and a rolling PE ratio of 211.49, marking a new low in 279 days [1] - The total market capitalization of Lepu Medical is reported at 30.372 billion yuan, with the company ranking 113th in the medical device industry's PE ratio, which averages 54.32 [1][2] Group 2 - For the first quarter of 2025, Lepu Medical reported an operating income of 1.736 billion yuan, a year-on-year decrease of 9.67%, and a net profit of 379 million yuan, down 21.44% year-on-year [1] - The gross profit margin for Lepu Medical stands at 64.03% [1] - A total of 30 institutions hold shares in Lepu Medical, including 29 funds and 1 brokerage, with a combined holding of 19.85 million shares valued at 274 million yuan [1]

Core Viewpoint - On August 4, Aoyang Health's stock closed at 4.25 yuan, up 3.41%, with a rolling PE ratio of 114.91, marking a new low in 35 days, and a total market capitalization of 3.254 billion yuan [1] Company Summary - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1] - The company has received several honors, including third place in the 7th National Hospital Quality Circle Competition and recognition as a demonstration hospital for improving medical services [1] - Aoyang Hospital has signed a contract with the China Trauma Rescue Alliance to enhance its trauma rescue capabilities, significantly reducing mortality and disability rates among severely injured patients [1] - The company ranked 32nd in the non-public hospital top 100 list published by the Alipay Hospital Management Research Center and is second among county-level non-public hospitals nationwide [1] Industry Summary - The average PE ratio for the medical services industry is 47.79, with a median of 59.03, placing Aoyang Health at 39th in the industry ranking [2] - The latest quarterly report for Q1 2025 shows Aoyang Health achieved revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82%, with a gross profit margin of 15.09% [2] - Comparatively, the industry average PE (TTM) is 47.79, while Aoyang Health's PE (TTM) stands at 114.91, indicating a significant premium over the industry average [2]

Group 1 - The core viewpoint of the article highlights the performance and valuation of Hongye Futures, which has a current stock price of 12.09 yuan, a PE ratio of 275.06, and a total market capitalization of 12.184 billion yuan [1][2] - Hongye Futures operates in the diversified financial industry, which has an average PE ratio of 70.96 and a median of 29.30, placing Hongye Futures at the 20th position in the industry ranking [1][2] - As of January 10, 2025, Hongye Futures has 40,409 shareholders, a decrease of 517 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business activities of Hongye Futures include commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, and fund sales [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 643 million yuan, a year-on-year increase of 259.09%, and a net profit of 1.2032 million yuan, up 109.07% year-on-year [1]

Company Overview - Aibo Medical closed at 75.72 yuan on August 1, with a decline of 1.82%, resulting in a rolling PE ratio of 38.74 times and a total market capitalization of 14.644 billion yuan [1] - The company ranks 80th in the medical device industry, which has an average PE ratio of 53.65 times and a median of 37.22 times [1] Shareholder Information - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with key products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the latest quarterly report for Q1 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.5581 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Weili Medical, indicating a steady growth in revenue and profit, alongside a relatively low PE ratio compared to the industry average [1][2] - As of August 1, Weili Medical's stock closed at 14.16 yuan, with a PE ratio of 17.69 times and a total market capitalization of 4.147 billion yuan [1] - The medical device industry has an average PE ratio of 53.65 times, with Weili Medical ranking 40th among its peers [1][2] Group 2 - For the first half of 2025, Weili Medical reported a revenue of 745 million yuan, representing a year-on-year increase of 10.19%, and a net profit of 121 million yuan, up 14.17% year-on-year [1] - The company's gross profit margin stands at 45.04%, indicating a strong profitability in its operations [1] - The company specializes in the research, production, and sales of medical catheters in various fields, including anesthesia, urology, respiratory care, and hemodialysis [1]

中国石油化工股份有限公司的主营业务为石油及天然气和化工业务。石油及天然气业务包括勘探、开发 及生产原油及天然气；管输原油、天然气；将原油提炼为石油制成品；以及营销原油、天然气和成品 油。化工业务包括制造及营销广泛的工业用化工产品。是中国大型油气生产商；炼油能力排名中国第一 位；在中国拥有完善的成品油销售网络，是中国最大的成品油供应商；乙烯生产能力排名中国第一位， 构建了比较完善的化工产品营销网络。 最新一期业绩显示，2025年一季报，公司实现营业收入7353.56亿元，同比-6.91%；净利润132.64亿元， 同比-27.60%，销售毛利率15.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5中国石化15.2413.710.836898.85亿行业平均 12.7711.481.201822.90亿行业中值30.5334.601.6461.42亿1中国海油9.158.941.5712329.27亿2中国石油 9.409.461.0015575.09亿3广汇能源12.1711.701.25346.45亿4*ST新潮13.5813.431.19273.38亿6洲际油气 22.8920.341.1 ...